Timken Publishes Q3 2026 Earnings Call Transcript
Bitget2026/11/05 14:14- Timken raised its 2026 adjusted earnings outlook to $6.35-$6.50 per share, implying 20% growth at the midpoint.
- The November 4 third-quarter earnings call featured CEO Lucian Boldea, CFO Michael A. Discenza and investor relations head Neil Frohnapple.
- Quarterly adjusted earnings reached $1.65 per share, including a $0.13 benefit from tariff refunds.
- Management expects mid-single-digit organic sales growth in 2027, including the impact of automotive original-equipment exits.
- The completed belts divestiture is expected to lift Industrial Motion EBITDA margins by more than 200 basis points next year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.